Zygel is a small molecule commercialized by Zynerba Pharmaceuticals, with a leading Phase III program in Fragile X Syndrome. According to Globaldata, it is involved in 16 clinical trials, of which 12 were completed, 2 are ongoing, and 2 are planned. GlobalData uses proprietary data and analytics to provide a complete picture of Zygel’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

The revenue for Zygel is expected to reach an annual total of $169 mn by 2034 globally based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Zygel Overview

Cannabidiol (ZYN-002) is under development for the treatment of neuropsychiatric disorders including developmental epileptic encephalopathy in children and adolescents, Fragile X syndrome in children and adolescents, adult refractory focal seizures, pediatric autism spectrum disorder (ASD) (pervasive developmental disorder) and 22q11.2 deletion syndrome. It is applied transdermally as a gel. The drug candidate targets cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors and also fatty acid amide hydrolase. It was also under development for the treatment of rheumatoid arthritis and knee pain due to osteoarthritis. It was under development for drug and alcohol addiction.

Zynerba Pharmaceuticals Overview

Zynerba Pharmaceuticals, formerly AllTranz, is a developer of next-generation synthetic cannabinoid therapeutics. The company produce transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. The company provides pipeline product candidates includes ZYN002. Its ZYN002 is a synthetic CBD, a non- cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery. Zynerba Pharmaceuticals’s ZYN002 is administered as a transdermal gel to children and adolescents with autism spectrum disorder. The company’s pipeline candidates target various indications which include refractory epileptic focal, fragile x syndrome, developmental and epileptic encephalopathies and autism spectrum disorder. Zynerba Pharmaceuticals is headquartered in Devon, Pennsylvania, the US.

The operating loss of the company was US$35.3 million in FY2022, compared to an operating loss of US$36.8 million in FY2021. The net loss of the company was US$35 million in FY2022, compared to a net loss of US$37.3 million in FY2021.

For a complete picture of Zygel’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.